Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Fibrotic Sarcoidosis
NCT06479603Phase 4Recruiting
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in pulmonary sarcoidosis comparing Nintedanib with Standard of care (2 arms). Primary endpoint: Forced Vital Capacity at 12 months. Started Jun 2024; status: recruiting.
02
Drugs
nintedanib
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NCT06479603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06479603.